Press Releases and Position Statements

SEPTEMBER 7	Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan
SEPTEMBER 1	Joint Statement from Moderna and Takeda on the Investigation of Suspended Lots of Moderna’s COVID-19 Vaccine in Japan
AUGUST 28	Moderna and Takeda’s Response to the Incidents Announced by the Japanese Ministry of Health, Labour and Welfare (MHLW) associated with the Announced Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan
AUGUST 26	Notice of Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan (COVID-19 Vaccine Moderna Intramuscular Injection)
JUNE 20	Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government
MAY 21	Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
MAY 10	Takeda Announces Positive Interim Safety and Immunogenicity Data from its Phase 1/2 Study of Moderna’s COVID-19 Vaccine Candidate (TAK-919) in Japan
APRIL 2	CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
MARCH 15	Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
MARCH 5	Takeda Submits New Drug Application to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan
FEBRUARY 24	Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
JANUARY 21	Start of a Japanese Clinical Study of TAK-919, Moderna’s COVID-19 Vaccine Candidate
DECEMBER 2	COVID-19 and the Role of Diagnostic Testing for Asymptomatic and Pre-Symptomatic Individuals
DECEMBER 1	World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19
OCTOBER 29	Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
OCTOBER 9	First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
OCTOBER 1	19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium
AUGUST 7	Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
AUGUST 3	Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial
MAY 26	Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation
MAY 7	CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
APRIL 6	Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
MARCH 25	Takeda Research & Development and COVID-19
MARCH 23	Coronavirus and Product Supply
MARCH 4	Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19